Methodological guidance for the evaluation and updating of clinical prediction models: a systematic review
MAE Binuya, EG Engelhardt, W Schats… - BMC Medical Research …, 2022 - Springer
Background Clinical prediction models are often not evaluated properly in specific settings
or updated, for instance, with information from new markers. These key steps are needed …
or updated, for instance, with information from new markers. These key steps are needed …
Identification of Patients with Early HR+ HER2− Breast Cancer at High Risk of Recurrence
PA Fasching, H Kreipe, L Del Mastro… - Geburtshilfe und …, 2024 - thieme-connect.com
Breast cancer incidence has increased in the last two decades and, simultaneously, survival
has improved due to earlier detection and improved treatment options. Despite this …
has improved due to earlier detection and improved treatment options. Despite this …
PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants
TA Muranen, A Morra, S Khan, DR Barnes… - NPJ breast …, 2023 - nature.com
We assessed the PREDICT v 2.2 for prognosis of breast cancer patients with pathogenic
germline BRCA1 and BRCA2 variants, using follow-up data from 5453 BRCA1/2 carriers …
germline BRCA1 and BRCA2 variants, using follow-up data from 5453 BRCA1/2 carriers …
Nomograms for Predicting Disease-Free Survival Based on Core Needle Biopsy and Surgical Specimens in Female Breast Cancer Patients with Non-Pathological …
A Lan, H Li, J Chen, M Shen, Y Jin, Y Dai… - Journal of Personalized …, 2023 - mdpi.com
Purpose: While a pathologic complete response (pCR) is regarded as a surrogate endpoint
for pos-itive outcomes in breast cancer (BC) patients receiving neoadjuvant chemotherapy …
for pos-itive outcomes in breast cancer (BC) patients receiving neoadjuvant chemotherapy …
[HTML][HTML] External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative …
Y Wang, A Broeks, D Giardiello, M Hauptmann… - European Journal of …, 2023 - Elsevier
Background The validity of the PREDICT breast cancer prognostic model is unclear for
young patients without adjuvant systemic treatment. This study aimed to validate PREDICT …
young patients without adjuvant systemic treatment. This study aimed to validate PREDICT …
Evaluation of Predict, a prognostic risk tool, after diagnosis of a second breast cancer
Abstract Background The UK National Health Service's Predict is a clinical tool widely used
to estimate the prognosis of early-stage breast cancer. The performance of Predict for a …
to estimate the prognosis of early-stage breast cancer. The performance of Predict for a …
[HTML][HTML] The use and misuse of risk prediction tools for clinical decision-making
MC van Maaren, TA Hueting, V Völkel, M van Hezewijk… - The Breast, 2023 - Elsevier
Risk prediction tools are of great value in supporting clinical decision-making: they can
identify, for example, the potential benefit of a treatment on prognosis of an individual …
identify, for example, the potential benefit of a treatment on prognosis of an individual …
Expression of transglutaminase-2 (TGM2) in the prognosis of female invasive breast cancer
Abstract Background Transglutaminase 2 (TGM2) is a protein expressed in several isoforms
in both intra-and extra-cellular tissue compartments. It has multiple functions that are …
in both intra-and extra-cellular tissue compartments. It has multiple functions that are …
[PDF][PDF] External alidation and clinical utilit assessment of PREDICT breast cancer prognostic model in oung, s stemic treatment-naï e omen ith node-negati e breast …
MK Schmidt - European Journal of Cancer, 2023 - scholarlypublications …
Background: The validity of the PREDICT breast cancer prognostic model is unclear for
young patients without adjuvant systemic treatment. This study aimed to validate PREDICT …
young patients without adjuvant systemic treatment. This study aimed to validate PREDICT …
Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2− breast cancer: A retrospective cohort study
Y Xie, X Li, Y Wu, W Cui, Y Liu - World Journal of Surgical Oncology, 2022 - Springer
Background The purpose of this study was to explore a new estrogen receptor (ER) and/or
progesterone receptor (PR)+ and human epidermal growth factor receptor 2 (HER2)− breast …
progesterone receptor (PR)+ and human epidermal growth factor receptor 2 (HER2)− breast …